Tetragenetics, Inc. is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. We accomplish this by harnessing the unique biology of Tetrahymena thermophila. Our technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease. Development of recombinant subunit vaccines against human pathogens is now underway, and long-range efforts are being directed towards large-scale expression of genetically engineered monoclonal antibodies. Additionally, we are actively pursuing both an internal pipeline of hard-to-make proteins and monoclonal antibodies, as well as proteins in partnership with a number of biopharmaceutical companies.
Modigene Inc. is a development-stage biopharmaceutical company utilizing technology to develop versions of approved therapeutic proteins. Modigene uses the Carboxyl Terminal Peptide (CTP) technology to develop versions of certain existing therapeutic proteins that have longer life spans. On May 9, 2007, the Company enter into an Agreement and Plan of Merger and Reorganization with Modigene Acquisition Corp., its wholly owned subsidiary, and Modigene Inc. (Modigene Delaware). Modigene Delaware is the parent company of ModigeneTech Ltd. On May 9, 2007, pursuant to the merger agreement, Modigene Acquisition merged with and into Modigene Delaware, with Modigene Delaware remaining as the surviving corporation. As a result of the merger, Modigene Delaware and ModigeneTech became Modigene's wholly owned subsidiaries and it acquired their business operations. (Source: 10KSB)
XstalBio Ltd is an advanced drug delivery company specialising in the formulation and stabilisation of therapeutic proteins, peptides, DNA and vaccines. XstalBio has developed proprietary formulation technology that has the potential to create new product opportunities, improve the therapeutic value, accelerate the development and extend the product life-cycles of protein-based drugs. Protein coated micro crystals (PCMC) provide a highly differentiated method for preparing biomolecules as stable solid-state formulations and the particles may be engineered for a wide range of delivery options including parenteral, pulmonary, sustained release and transdermal routes. XstalBio Ltd is already collaborating with leading pharmaceutical and biotechnology companies and we continue to seek pharmaceutical partners for licensing and co-development of the PCMC technology for their proprietary molecules. XstalBio can also provide vaccine, pharmaceutical and biotechnology companies active in the delivery and stabilisation of proteins or vaccines an immediate competitive advantage by offering significant advancement in Circular Dichroism (CD) analysis. Conventional CD is used to elucidate the structural aspects of protein conformation in solution but cannot be applied to particles. An innovative, yet simple, rotating CD cell holder has been developed by XstalBio to provide rapid, reliable information on the secondary and tertiary structure of proteins in the solid state. This powerful tool enables faster and more cost effective analysis of formulations; yet can be easily slotted into existing CD instruments and used with freely available software packages. Evaluation and utilisation of the CD technology is a straight-forward technology transfer process with full training being offered to key users.
Osprey Pharmaceuticals Limited is a privately held biotechnology company focused on commercializing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's patented Leukocyte Population Modulators selectively and systematically destroy these disease-related leukocytes by infiltrating the chemokine system - a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The company expects to initiate a Phase I/II trial for chronic kidney disease in the second half of 2007. Osprey has developed a portfolio of 12 preclinical product candidates addressing a variety of diseases including cancer, cardiovascular disease, and neurological disorders, and the company anticipates initiating at least one clinical trial annually over the next three years. Osprey minimizes the risks inherent to drug development and commercialization by using a technology that can rapidly generate new product candidates, and then uniformly applying standardized testing and manufacturing protocols across its portfolio.
Medicago, a world leader in plant-made pharmaceuticals, uses alfalfa plants as living, bio-safe factories to deliver high-value active elements to the human health, cosmeceutical, industrial sectors and numerous others. Located in Québec City, Medicago offers a French dynamic working environment with high-tech offices and equipment, competitive salaries, a health plan and a stock option program. Medicago offers interesting career opportunities in the following fields: Agronomy Molecular biology, cellular or agricultural Biochemistry Analytical chemistry In-vitro culture Microbiology Protein purification Administration If you are a dynamic, motivated and skillful person, ready to face the many challenges of our high-tech business sector, don't hesitate to send us your resume. Until a position opens up, we will confidentially keep your resume in our files for a period of 6 months. If you wish to submit your application, don't hesitate to send your resume by mail, fax or email at the following address: MEDICAGO inc. Human resources services 1020, route de l'Église Sainte-Foy (Québec) G1V 3V9 Fax: (418) 658-6699 Email: rh-hr@medicago.com We hope that you will add this page to your « favorites » in order to regularly consult the posted details of available positions during our recruitment process. Medicago is an equal opportunity employer. We thank you for your resume, however, please take note that only the persons selected for an interview will be contacted.
QSV Biologics, Ltd. is a North American based cGMP biologics contract manufacturer providing mammalian cell culture, microbial fermentation and purification services for the production of protein therapeutics, monoclonal antibodies, vaccines and diagnostics. Our facility has a 10 year track record and is licensed for cGMP manufacture of pre-clinical, clinical and commercial supply. QSV recently underwent a comprehensive GMP compliance audit by Health Canada's Health Products and Food Branch Inspectorate (HPFBI) and was found to be compliant with all applicable regulations and guidelines. QSV's market consists of Canadian, U.S., Australian, Asian and European biotechnology firms with protein therapeutics in development. As a dedicated biopharmaceutical contract manufacturer, QSV provides the following services: cGMP Microbial Fermentation Microbial Process Development Upstream and Downstream Mammalian Cell Culture Process Development Upstream and Downstream cGMP Cell Bank Development & Storage Analytical Development Process & Analytical Validation Process Scale Up cGMP Document Services Technology Transfer Quality is your first consideration when selecting a contract manufacturer. Quality is our first priority! More information can be obtained by contacting: Richard Hetrick Business Development Phone: (484) 678 - 4820 Phone: (780) 438 - 7143 Fax: (610) 873 - 8453 Email: rhetrick@qsvbiologics.com
Chlorogen, Inc. is a biotechnology company that specializes in the expression of pharmaceutical proteins in the chloroplasts of plants. Through its patented chloroplast transformation technology, Chlorogen is committed to being a world-class producer of beneficial proteins for human therapy. In addition to co-developing our own pharmaceutical pipeline, we are selectively outlicensing CTTÔ technology for use in other markets, such as food and feed and biodefense.
Cobra provides services to clients worldwide from its two facilities in Oxford and Keele, United Kingdom, our main country of operation. The Company's VAT number is GB 792 4067 11. "Cobra is a leading cGMP compliant contract manufacturer of biopharmaceuticals. Our expertise and over 15 years of experience in producing biopharmaceuticals, including proteins, viruses, DNA and cells for use in pre-clinical to Phase III clinical trials, are the overwhelming reasons why our clients from the global life sciences market partner with Cobra."
http://www.ppl-therapeutics.com
PPL Therapeutics is a biopharmaceutical company which is one of the world¡¯s leaders in the application of transgenic animal technologies to the development and production of human proteins for therapeutic and nutritional applications. PPL has a broad pipeline of diverse protein products including AAT, the Company¡¯s lead product, which is currently in Phase II clinical trials for cystic fibrosis. AAT is also under development for the treatment of congenital deficiency. PPL¡¯s other lead products are fibrinogen and bile salt stimulated lipase (BSSL). Transgenic production of human proteins involves the introduction of copies of human DNA into the genetic material of another species. The resulting transgenic animals express the human gene product (protein) in the mammary gland allowing its collection and purification during lactation. The technique offers the opportunity to produce human proteins economically and in potentially unlimited quantities. PPL has a world wide exclusive licence from the Roslin Institute to use the Institute¡¯s intellectual property relating to nuclear transfer (cloning) in the field of production of proteins for pharmaceutical and nutraceutical use in the milk of ruminant livestock and rabbits.
Cangene Corporation (Cangene) is a Canada-based biopharmaceutical company. The Company is engaged in the business of developing, manufacturing, and commercializing products and technologies for global markets. The business segments of the Company are biopharmaceutical operations and contract services. The two types of products of the Company includes hyperimmunes, which are concentrated specialty antibody preparations made from plasma, and recombinant biopharmaceuticals, which are therapeutic proteins made by introducing a particular gene into a host organism, which in turn produces the protein of interest. Its hyperimmune products include VariZIG (varicella zoster immune globulin), VIG (vaccinia immune globulin) and HepaGam B (hepatitis B immune globulin). Its recombinant biopharmaceutical products include Leucotropin and Accretropin. (Source: ARS)
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory